The present invention relates to a novel combination drug in a solid oral dosage form comprising, as one of the three active ingredients, elsulfavirine sodium that may be suitable for medical use when treating viral infections including HIV and HBV.

An antiviral combination drug in a solid oral dosage form comprising, as one of the three active ingredients, a therapeutically effective amount of elsulfavirine sodium of formula 1a in a crystalline or polycrystalline form optionally in combination with auxiliary agents:

##STR00001##

The present invention relates to compounds of the general formula (I) ##STR00001##
in which Q, V, T, W, X, Y and A have the meanings given in the descriptionand to their use for controlling animal pests.

The present invention relates to compounds of the general formula (I) ##STR00001##
in which Q, V, T, W, X, Y and A have the meanings given in the descriptionand to their use for controlling animal pests.

Provided are compounds that generate a peroxide when they react with ozone in the presence of water. Additionally, alkyne compounds reactive with a free radical, a reactive oxygen species (ROS) or another reactive species are provided. Also provided are enol ether, enamine, and vinal thioester compounds reactive with a free radical, a strong acid, a reactive oxygen species (ROS) or another reactive species. Additionally provided are compounds reactive with a free radical, an ROS or another reactive species. The compounds comprise a conjugated moiety operably joined to an alkene moiety and a resonance-transmitting moiety, wherein the resonance-transmitting moiety transmits an electron through the conjugated moiety to the alkene moiety, which reacts with the free radical, an ROS or another reactive species. Also provided are methods of decomposing a free radical, an ROS or another reactive species. The methods comprise contacting the free radical or ROS with any of the above compounds. Also provided are methods of using any of the compounds described herein, and compositions comprising those compounds. Additionally provided are methods of producing the above compounds.

The present invention includes fused tetraphenylene compounds that may be used as charge transporters, hosts or emitters in OLEDs.

The present invention includes fused tetraphenylene compounds that may be used as charge transporters, hosts or emitters in OLEDs.

The present invention provides (i) processes for preparing a 2-deoxy-2-fluoro-2-methyl-D-ribonolactone derivatives, (ii) conversion of intermediate lactones to nucleosides with potent anti-HCV activity, and their analogues, and (iii) methods to prepare the anti-HCV nucleosides containing the 2-deoxy-2-fluoro-2-C-methyl--D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.

The present invention provides (i) processes for preparing a 2-deoxy-2-fluoro-2-methyl-D-ribonolactone derivatives, (ii) conversion of intermediate lactones to nucleosides with potent anti-HCV activity, and their analogues, and (iii) methods to prepare the anti-HCV nucleosides containing the 2-deoxy-2-fluoro-2-C-methyl--D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.

The present invention provides a composition comprising nanoparticles of prodrugs of certain pharmaceutically active agents, wherein the nanoparticles of prodrugs are dispersed within a carrier material. The present invention further provides processes for the making of the same.

The present invention provides a composition comprising nanoparticles of prodrugs of certain pharmaceutically active agents, wherein the nanoparticles of prodrugs are dispersed within a carrier material. The present invention further provides processes for the making of the same.